Advertisement
Canada markets close in 3 hours 59 minutes
  • S&P/TSX

    22,373.02
    +113.86 (+0.51%)
     
  • S&P 500

    5,198.49
    +10.82 (+0.21%)
     
  • DOW

    39,217.27
    +160.88 (+0.41%)
     
  • CAD/USD

    0.7304
    +0.0016 (+0.22%)
     
  • CRUDE OIL

    79.10
    +0.11 (+0.14%)
     
  • Bitcoin CAD

    85,055.01
    -212.84 (-0.25%)
     
  • CMC Crypto 200

    1,337.40
    +37.31 (+2.87%)
     
  • GOLD FUTURES

    2,336.70
    +14.40 (+0.62%)
     
  • RUSSELL 2000

    2,065.02
    +9.89 (+0.48%)
     
  • 10-Yr Bond

    4.4830
    -0.0090 (-0.20%)
     
  • NASDAQ

    16,316.76
    +14.00 (+0.09%)
     
  • VOLATILITY

    13.14
    +0.14 (+1.08%)
     
  • FTSE

    8,381.35
    +27.30 (+0.33%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • CAD/EUR

    0.6778
    +0.0002 (+0.03%)
     

Why Investors Loved Moderna's Q3 Results

Why Investors Loved Moderna's Q3 Results

Moderna's (NASDAQ: MRNA) primary focus right now is to hopefully win regulatory approvals or authorizations for coronavirus vaccine mRNA-1273 to make it to the market. Moderna reported revenue in the third quarter of $157.9 million, up a whopping 829% year over year. Perhaps the most important financial measure for Moderna was its cash position at the end of the third quarter.